Advancing the Discovery & Development of Peptide Drugs with Novel Screening, Chemistry, Formulation & CMC to Improve Permeability, Bioavailability & Efficacy Across All Diseases
Peptide therapies are rapidly becoming a disruptive modality, with Unnatural Products scoring a potential $1.7bn licensing agreement with Novartis for macrocyclic peptide therapeutics and Zonsen PepLib Biotech entering R&D collaboration with Eli Lilly to advance the novel peptide-based drugs in the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.
To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments.
Gathering industry leaders including Unnatural Products, Parabilis Medicines, Circle Pharma, Abbvie, Eli Lilly, Merck, Johnson & Johnson, Chugai Pharmaceuticals, Bayer and many more, this is your premium forum to explore the power of peptide computation, optimizing analytics, improving oral bioavailability and translating the pharmacology with clinical safety.
Join 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D, medicinal chemistry, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization.
This Summit will provide a deep learning experience for all peptide drug hunters and an opportunity to meet accomplished R&D leaders as well as share their scientific work as speakers or via poster presentations.
Tomi Sawyer, Maestro Therapeutics
I see the summit as a great opportunity to meet other participants with a strong dedication to peptide therapeutics and who share the goal of oral peptide delivery.
Florian Foeger, Cyprumed
As an investor, I look forward to meeting with the companies and thought leaders at the forefront of the peptide therapeutics space.
Alex Loftis, Vida Ventures
Download the Full Event Guide
- Learn from 40+ Expert Speakers
- NEW Two-Track Agenda covering Drug Discovery and Formulation & CMC
- NEW Business Development & Investment Panel
- 4 Deep-Dive Workshops
- 25+ Data-Driven Case Studies
Poster Session
The Scientific Poster Session offers a dedicated forum for researchers to share emerging data, spark discussion, and connect with peers working across peptide-focused drug development. Attendees will explore new approaches, exchange practical insights, and discover innovations shaping the next generation of therapeutics.
How It Works:
Registered attendees are invited to submit an abstract for review. Accepted presenters will receive detailed guidance on poster specifications and are asked to provide a digital version in advance of the meeting.
Key Dates:
- Scientific Poster Session: Wednesday, April 29, 2026
- Abstract Submission Deadline: Friday, April 10, 2026
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.